Nicolas Desroy
Galapagos (France)(FR)
Publications by Year
Research Areas
Synthetic Organic Chemistry Methods, Sphingolipid Metabolism and Signaling, Asymmetric Synthesis and Catalysis, Drug Transport and Resistance Mechanisms, Chronic Lymphocytic Leukemia Research
Most-Cited Works
- → Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2- a ]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis(2017)137 cited
- → Discovery of new Gram-negative antivirulence drugs: Structure and properties of novel E. coli WaaC inhibitors(2008)90 cited
- → Towards Gram-negative antivirulence drugs: New inhibitors of HldE kinase(2008)72 cited
- → Discovery, Structure–Activity Relationship, and Binding Mode of an Imidazo[1,2-a]pyridine Series of Autotaxin Inhibitors(2017)60 cited
- → From Triclosan toward the Clinic: Discovery of Nonbiocidal, Potent FabI Inhibitors for the Treatment of Resistant Bacteria(2012)54 cited
- → Identification of GLPG/ABBV-2737, a Novel Class of Corrector, Which Exerts Functional Synergy With Other CFTR Modulators(2019)39 cited
- → An Efficient Route to 4/5/6 Polycyclic β‐Lactams(2004)30 cited
- → Ruthenium-SYNPHOS-Catalyzed Asymmetric Hydrogenations: an Entry to Highly Stereoselective Synthesis of the C15−C30 Subunit of Dolabelide A(2008)27 cited
- → Stereoselective synthesis of C15-C24 and C25-C30 fragments of dolabelides(2003)24 cited
- → Discovery of Clinical Candidate GLPG3970: A Potent and Selective Dual SIK2/SIK3 Inhibitor for the Treatment of Autoimmune and Inflammatory Diseases(2024)21 cited